Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer
2014 San Antonio Breast Cancer Symposium
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.
Harold J Burstein MD PhD and Lisa A Carey MD
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
- The TNT trial comparing docetaxel to carboplatin
- The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
- Pembrolizumab in a phase Ib study
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Jack Cuzick, PhD
Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
